All questionsClinical trials: Eliquis (apixaban) in nonvalvular atrial fibrillation9 questions · 2 sourcesARISTOTLE trialEliquis vs warfarin: how was the ARISTOTLE trial designed?“A pivotal, phase III, randomized, double-blind clinical trial designed to compare the effects of ELIQUIS 5 mg twice daily‡ (n=9120) and warfarin (n=9081) (target international normalized ratio [INR] range: 2.0–3.0) in reducing the risk of stroke and systemic embolism (SE) in 18,201 patients with NVAF and ≥1 risk factors for stroke: prior stroke or transient ischemic attack (TIA), prior SE, ≥75 years of age, arterial hypertension requiring treatment, diabetes mellitus, heart failure ≥New York Heart Association (NYHA) Class 2, or decreased left ventricular ejection fraction (LVEF) ≤40%.1-3 Patients were followed for a median of ≈1.7 years. The 2 treatment groups were well balanced with respect to baseline characteristics, including age, stroke risk (CHADS2 score),§ and prior vitamin K antagonist (VKA) experience.2 The primary efficacy endpoint was stroke/systemic embolism, and the primary safety endpoint was major bleeding.1” (opens the source at this quote in a new tab)CopyFlag“A dose of 2.5 mg twice daily was assigned to patients with at least 2 of the following characteristics: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL.” (opens the source at this quote in a new tab)CopyFlagIs Eliquis better than warfarin at preventing stroke in atrial fibrillation (ARISTOTLE)?“A total of 18,201 patients were randomized and followed on study treatment for a median of 89 weeks.” (opens the source at this quote in a new tab)CopyFlag“ELIQUIS was superior to warfarin for the primary endpoint of reducing the risk of stroke and systemic embolism (Table 13 and Figure 4). Superiority to warfarin was primarily attributable to a reduction in hemorrhagic stroke and ischemic strokes with hemorrhagic conversion compared to warfarin. Purely ischemic strokes occurred with similar rates on both drugs.” (opens the source at this quote in a new tab)CopyFlag“Table 13: Key Efficacy Outcomes in Patients with Nonvalvular Atrial Fibrillation in ARISTOTLE (Intent-to-Treat Analysis) ELIQUIS N=9120 n (%/year) Warfarin N=9081 n (%/year) Hazard Ratio (95% CI) P-value Stroke or systemic embolism 212 (1.27) 265 (1.60) 0.79 (0.66, 0.95) 0.01 Stroke 199 (1.19) 250 (1.51) 0.79 (0.65, 0.95) Ischemic without hemorrhage 140 (0.83) 136 (0.82) 1.02 (0.81, 1.29) Ischemic with hemorrhagic conversion 12 (0.07) 20 (0.12) 0.60 (0.29, 1.23) Hemorrhagic 40 (0.24) 78 (0.47) 0.51 (0.35, 0.75) Unknown 14 (0.08) 21 (0.13) 0.65 (0.33, 1.29) Systemic embolism 15 (0.09) 17 (0.10) 0.87 (0.44, 1.75) The primary endpoint was based on the time to first event (one per subject). Component counts are for subjects with any event, not necessarily the first.” (opens the source at this quote in a new tab)CopyFlagDoes Eliquis cause less major bleeding than warfarin (ARISTOTLE)?“Table 2: Bleeding Events in Patients with Nonvalvular Atrial Fibrillation in ARISTOTLE* ELIQUIS N=9088 n (per 100 pt-year) Warfarin N=9052 n (per 100 pt-year) Hazard Ratio (95% CI) P-value Major† 327 (2.13) 462 (3.09) 0.69 (0.60, 0.80) <0.0001” (opens the source at this quote in a new tab)CopyFlag“Bleeding events within each subcategory were counted once per subject, but subjects may have contributed events to multiple endpoints. Bleeding events were counted during treatment or within 2 days of stopping study treatment (on-treatment period). † Defined as clinically overt bleeding accompanied by one or more of the following: a decrease in hemoglobin of ≥2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal or with fatal outcome.” (opens the source at this quote in a new tab)CopyFlag“ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding.” (opens the source at this quote in a new tab)CopyFlagDoes Eliquis cause less intracranial or fatal bleeding than warfarin (ARISTOTLE)?“There were significantly fewer ICH events vs warfarin. Hemorrhagic stroke#: 0.24%/yr (n=38/9088) vs 0.49%/yr (n=74/9052), HR=0.51 (95% CI: 0.34-0.75); other ICH: 0.10%/yr (n=15/9088) vs 0.34%/yr (n=51/9052), HR=0.29 (95% CI: 0.16-0.51)1 There were significantly fewer fatal bleeding events vs warfarin. Intracranial: 0.03%/yr (n=4/9088) vs 0.20%/yr (n=30/9052), HR=0.13 (95% CI: 0.05-0.37); nonintracranial: 0.04%/yr (n=6/9088) vs 0.05%/yr (n=7/9052), HR=0.84 (95% CI: 0.28-2.15)1” (opens the source at this quote in a new tab)CopyFlag“On-treatment analysis based on the safety population, compared to intent-to-treat analysis presented in efficacy population.” (opens the source at this quote in a new tab)CopyFlag“Table 2: Bleeding Events in Patients with Nonvalvular Atrial Fibrillation in ARISTOTLE* ELIQUIS N=9088 n (per 100 pt-year) Warfarin N=9052 n (per 100 pt-year) Hazard Ratio (95% CI) P-value Major† 327 (2.13) 462 (3.09) 0.69 (0.60, 0.80) <0.0001 Intracranial (ICH)‡ 52 (0.33) 125 (0.82) 0.41 (0.30, 0.57) - Hemorrhagic stroke§ 38 (0.24) 74 (0.49) 0.51 (0.34, 0.75) - Other ICH 15 (0.10) 51 (0.34) 0.29 (0.16, 0.51) - Gastrointestinal (GI)¶ 128 (0.83) 141 (0.93) 0.89 (0.70, 1.14) - Fatal # 10 (0.06) 37 (0.24) 0.27 (0.13, 0.53) -” (opens the source at this quote in a new tab)CopyFlagDid Eliquis lower the risk of death compared with warfarin in ARISTOTLE?“All-cause death was assessed using a sequential testing strategy that allowed testing for superiority if effects on earlier endpoints (stroke plus systemic embolus and major bleeding) were demonstrated. ELIQUIS treatment resulted in a significantly lower rate of all-cause death (p = 0.046) than did treatment with warfarin, primarily because of a reduction in cardiovascular death, particularly stroke deaths. Non-vascular death rates were similar in the treatment arms.” (opens the source at this quote in a new tab)CopyFlag“Cardiovascular deaths (1.80%/year vs 2.02%/year, HR=0.89 [95% CI: 0.76–1.04]), particularly stroke deaths (0.42% vs 0.72%), were the greatest contributors to the reduction in all-cause mortality vs warfarin2,4 The incidence of nonvascular mortality was similar in patients taking ELIQUIS to that in patients taking warfarin (1.14%/year vs 1.22%/year, HR=0.93 [95% CI: 0.77–1.13])2” (opens the source at this quote in a new tab)CopyFlagWere Eliquis results consistent across patient subgroups in ARISTOTLE?“In ARISTOTLE, the results for the primary efficacy endpoint were generally consistent across most major subgroups including weight, CHADS2 score (a scale from 0 to 6 used to predict risk of stroke in patients with AF, with higher scores predicting greater risk), prior warfarin use, level of renal impairment, geographic region, and aspirin use at randomization (Figure 5).” (opens the source at this quote in a new tab)CopyFlag“In ARISTOTLE, the results for major bleeding were generally consistent across most major subgroups including age, weight, CHADS2 score (a scale from 0 to 6 used to estimate risk of stroke, with higher scores predicting greater risk), prior warfarin use, geographic region, and aspirin use at randomization (Figure 1). Subjects treated with ELIQUIS with diabetes bled more (3% per year) than did subjects without diabetes (1.9% per year).” (opens the source at this quote in a new tab)CopyFlag“Patients with diabetes who were treated with ELIQUIS bled more than patients without diabetes (3.0%/year vs 1.9%/year, respectively). Major bleeds were observed in ELIQUIS and warfarin patients with diabetes at a rate of 3.0%/year and 3.1%/year, respectively.” (opens the source at this quote in a new tab)CopyFlag“Note: The figure above presents effects in various subgroups, all of which are baseline characteristics and all of which were prespecified, if not the groupings. The 95% confidence limits that are shown do not take into account how many comparisons were made, nor do they reflect the effect of a particular factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted.” (opens the source at this quote in a new tab)CopyFlagWere Eliquis results in ARISTOTLE consistent in patients with reduced kidney function?“Generally consistent efficacy across levels of renal function in ARISTOTLE in the reduction of the risk of stroke/systemic embolism1,2 Results from a prespecified subgroup analysis†† of NVAF patients Patients with a serum creatinine level of >2.5 mg/dL or calculated creatinine clearance of <25 mL/min were excluded from the ARISTOTLE trial2 In the ARISTOTLE trial, 5319 patients in the ELIQUIS arm had various levels of renal impairment1” (opens the source at this quote in a new tab)CopyFlag“Stroke and Systemic Embolism Hazard Ratios by Baseline Characteristics” (opens the source at this quote in a new tab)CopyFlag“n of Events / N of Patients (% per year) Subgroup Apixaban Warfarin Hazard Ratio (95% CI)” (opens the source at this quote in a new tab)CopyFlag“Creatinine Clearance <30 mL/min (1%) 6 / 137 (2.8) 10 / 133 (5.1) 0.55 (0.20, 1.53) 30-50 mL/min (15%) 48 / 1365 (2.0) 59 / 1382 (2.5) 0.83 (0.57, 1.21) >50-80 mL/min (42%) 87 / 3817 (1.2) 116 / 3770 (1.7) 0.74 (0.56, 0.97) >80 mL/min (41%) 70 / 3761 (1.0) 79 / 3757 (1.1) 0.88 (0.64, 1.21)” (opens the source at this quote in a new tab)CopyFlag“Major Bleeding Hazard Ratios by Baseline Characteristics” (opens the source at this quote in a new tab)CopyFlag“n of Events / N of Patients (% per year) Subgroup Apixaban Warfarin Hazard Ratio (95% CI)” (opens the source at this quote in a new tab)CopyFlag“Creatinine Clearance <30 mL/min (1%) 7 / 136 (3.7) 19 / 132 (11.9) 0.32 (0.13, 0.78) 30-50 mL/min (15%) 66 / 1357 (3.2) 123 / 1380 (6.0) 0.53 (0.39, 0.71) >50-80 mL/min (42%) 157 / 3807 (2.5) 199 / 3758 (3.2) 0.76 (0.62, 0.94) >80 mL/min (41%) 96 / 3750 (1.5) 119 / 3746 (1.8) 0.79 (0.61, 1.04)” (opens the source at this quote in a new tab)CopyFlag“Note: The figures above present effects in one of various subgroups, all of which are baseline characteristics and all of which were prespecified, if not the groupings. The 95% confidence limits that are shown do not take into account how many comparisons were made, nor do they reflect the effect of a particular factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted.1” (opens the source at this quote in a new tab)CopyFlagAVERROES trialIs Eliquis more effective than aspirin at preventing stroke when warfarin is unsuitable (AVERROES)?“In AVERROES, patients with nonvalvular atrial fibrillation thought not to be candidates for warfarin therapy were randomized to treatment with ELIQUIS 5 mg orally twice daily (or 2.5 mg twice daily in selected patients) or aspirin 81 to 324 mg once daily. The primary objective of the study was to determine if ELIQUIS was superior to aspirin for preventing the composite outcome of stroke or systemic embolism. AVERROES was stopped early on the basis of a prespecified interim analysis showing a significant reduction in stroke and systemic embolism for ELIQUIS compared to aspirin that was associated with a modest increase in major bleeding (Table 14) [see Adverse Reactions (6.1)].” (opens the source at this quote in a new tab)CopyFlag“Table 14: Key Efficacy Outcomes in Patients with Nonvalvular Atrial Fibrillation in AVERROES ELIQUIS N=2807 n (%/year) Aspirin N=2791 n (%/year) Hazard Ratio (95% CI) P-value Stroke or systemic embolism 51 (1.62) 113 (3.63) 0.45 (0.32, 0.62) <0.0001 Stroke Ischemic or undetermined 43 (1.37) 97 (3.11) 0.44 (0.31, 0.63) - Hemorrhagic 6 (0.19) 9 (0.28) 0.67 (0.24, 1.88) - Systemic embolism 2 (0.06) 13 (0.41) 0.15 (0.03, 0.68) - MI 24 (0.76) 28 (0.89) 0.86 (0.50, 1.48) - All-cause death 111 (3.51) 140 (4.42) 0.79 (0.62, 1.02) 0.068 Vascular death 84 (2.65) 96 (3.03) 0.87 (0.65, 1.17) -” (opens the source at this quote in a new tab)CopyFlagDid Eliquis increase major bleeding compared with aspirin in AVERROES?“In another clinical trial (AVERROES), ELIQUIS was associated with an increase in major bleeding compared with aspirin that was not statistically significant (1.41%/year vs 0.92%/year, HR=1.54 [95% CI: 0.96–2.45]; P=0.07)” (opens the source at this quote in a new tab)CopyFlag“Table 3: Bleeding Events in Patients with Nonvalvular Atrial Fibrillation in AVERROES ELIQUIS N=2798 n (%/year) Aspirin N=2780 n (%/year) Hazard Ratio (95% CI) P-value Major 45 (1.41) 29 (0.92) 1.54 (0.96, 2.45) 0.07 Fatal 5 (0.16) 5 (0.16) 0.99 (0.23, 4.29) - Intracranial 11 (0.34) 11 (0.35) 0.99 (0.39, 2.51) - Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.” (opens the source at this quote in a new tab)CopyFlag“In AVERROES, the mean duration of exposure was approximately 59 weeks (>3000 patient-years).” (opens the source at this quote in a new tab)CopyFlag